NBLST1
MCID: NRB010
MIFTS: 49

Neuroblastoma 1 (NBLST1)

Categories: Cancer diseases, Endocrine diseases, Fetal diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuroblastoma 1

MalaCards integrated aliases for Neuroblastoma 1:

Name: Neuroblastoma 1 56 73 6
Nblst1 56 73
Neuroblastoma, Susceptibility to, Type 1 39
Neuroblastoma, Susceptibility to, 1 56

Characteristics:

OMIM:

56
Inheritance:
somatic mutation
autosomal dominant

Miscellaneous:
incomplete penetrance
genetic heterogeneity
mean age of onset 14-24 months
highly variable clinical phenotype
symptoms vary according to location of tumor
spontaneous tumor regression may occur
usually sporadic, but 1-2% of cases are familial
n-myc oncogene amplification is associated with poor prognosis


HPO:

31
neuroblastoma 1:
Inheritance autosomal dominant inheritance somatic mutation heterogeneous sporadic
Onset and clinical course incomplete penetrance


Classifications:



Summaries for Neuroblastoma 1

OMIM : 56 Neuroblastoma is the most common childhood cancer diagnosed before the age of 1 year, and accounts for 10 to 15% of all cancer deaths in children. Some patients inherit a genetic predisposition to neuroblastoma due to germline mutations, whereas others develop sporadic disease that may result from either germline or somatic mutations. Neuroblastoma tumors are derived from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system (Roberts et al., 1998; Eng, 2008). Histopathologically, neuroblastoma can range in type from the most aggressive form, neuroblastoma, composed entirely of immature neural precursor cells, to ganglioneuroma, composed entirely of mature neural tissue. The most important prognostic factor for patients with neuroblastoma is the extent of the tumor at the time of diagnosis (Roberts et al., 1998). Neuroblastoma can also be part of cancer-prone syndromes, such as paragangliomas (see, e.g., PGL4; 115310). (256700)

MalaCards based summary : Neuroblastoma 1, also known as nblst1, is related to neuroblastoma and alk-related neuroblastic tumor susceptibility. An important gene associated with Neuroblastoma 1 is KIF1B (Kinesin Family Member 1B), and among its related pathways/superpathways are Toll Comparative Pathway and Proteoglycans in cancer. The drugs 3-Iodobenzylguanidine and Radiopharmaceuticals have been mentioned in the context of this disorder. Affiliated tissues include bone, spinal cord and skin, and related phenotypes are failure to thrive and ataxia

UniProtKB/Swiss-Prot : 73 Neuroblastoma 1: A common neoplasm of early childhood arising from embryonic cells that form the primitive neural crest and give rise to the adrenal medulla and the sympathetic nervous system.

Related Diseases for Neuroblastoma 1

Graphical network of the top 20 diseases related to Neuroblastoma 1:



Diseases related to Neuroblastoma 1

Symptoms & Phenotypes for Neuroblastoma 1

Human phenotypes related to Neuroblastoma 1:

31 (show all 22)
# Description HPO Frequency HPO Source Accession
1 failure to thrive 31 HP:0001508
2 ataxia 31 HP:0001251
3 hypertension 31 HP:0000822
4 myoclonus 31 HP:0001336
5 fever 31 HP:0001945
6 anemia 31 HP:0001903
7 abdominal pain 31 HP:0002027
8 weight loss 31 HP:0001824
9 abnormality of the thorax 31 HP:0000765
10 diarrhea 31 HP:0002014
11 spinal cord compression 31 HP:0002176
12 bone pain 31 HP:0002653
13 neuroblastoma 31 HP:0003006
14 ganglioneuroma 31 HP:0003005
15 abdominal mass 31 HP:0031500
16 skin nodule 31 HP:0200036
17 horner syndrome 31 HP:0002277
18 ganglioneuroblastoma 31 HP:0006747
19 opsoclonus 31 HP:0010543
20 elevated urinary dopamine 31 HP:0011979
21 elevated urinary vanillylmandelic acid 31 HP:0011978
22 elevated urinary homovanillic acid 31 HP:0011977

Symptoms via clinical synopsis from OMIM:

56
Growth Other:
failure to thrive

Metabolic Features:
fever

Neoplasia:
ganglioneuroma
ganglioneuroblastoma
neuroblastoma, arises anywhere along the sympathetic chain (including intracranially)
adrenal glands are most common site

Head And Neck Eyes:
horner's syndrome
periorbital ecchymoses (soft tissue involvement)

Chest:
mediastinal mass with calcifications on radiology

Skeletal:
bone pain (with metastatic disease)

Hematology:
anemia (with bone marrow involvement)

Neurologic Central Nervous System:
ataxia
myoclonus
spinal cord compression
opsoclonus
paraneoplastic syndromes

Abdomen:
abdominal pain
palpable abdominal mass
abdominal mass with calcifications on radiology

Growth Weight:
weight loss (with disseminated disease)

Cardiovascular Vascular:
hypertension (compression of renal arteries)

Abdomen Gastrointestinal:
diarrhea (due to vasoactive intestinal peptide)

Skin Nails Hair Skin:
bluish skin nodules

Laboratory Abnormalities:
increased urinary catecholamines
increased urinary homovanillic acid (hva)
increased urinary vanillylmandelic acid (vma)
increased urinary dopamine
tumor may secrete vasoactive intestinal peptide (vip)

Clinical features from OMIM:

256700

MGI Mouse Phenotypes related to Neuroblastoma 1:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.06 ALK FGFR1 KIF1B NAV2 NBL1 PTPN11
2 homeostasis/metabolism MP:0005376 10.01 ALK FANCA FGFR1 KIF1B NAV2 PTPN11
3 mortality/aging MP:0010768 9.92 ALK FANCA FGFR1 KIF1B NAV2 PTPN11
4 integument MP:0010771 9.91 ALK FGFR1 KIF1B NAV2 NBL1 PTPN11
5 craniofacial MP:0005382 9.83 FANCA FGFR1 KIF1B PTPN11 TP53
6 nervous system MP:0003631 9.7 ALK FGFR1 KIF1B NAV2 PTPN11 TP53
7 muscle MP:0005369 9.65 FGFR1 KIF1B PTPN11 TP53 UBE4B
8 skeleton MP:0005390 9.5 ALK FANCA FGFR1 KIF1B NBL1 PTPN11
9 vision/eye MP:0005391 9.1 ALK FANCA FGFR1 NAV2 PTPN11 TP53

Drugs & Therapeutics for Neuroblastoma 1

Drugs for Neuroblastoma 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1 3-Iodobenzylguanidine
2 Radiopharmaceuticals

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma Approved for marketing NCT00730444 Iobenguane I 123 Injection
2 Melanocytic-Nevi-Counts During Chemotherapy of Children With Malignancies. Completed NCT00600431
3 An Open Label, Expanded Access Protocol Using 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Available NCT01838187

Search NIH Clinical Center for Neuroblastoma 1

Genetic Tests for Neuroblastoma 1

Anatomical Context for Neuroblastoma 1

MalaCards organs/tissues related to Neuroblastoma 1:

40
Bone, Spinal Cord, Skin, Bone Marrow, Adrenal Gland, Myeloid, Brain

Publications for Neuroblastoma 1

Articles related to Neuroblastoma 1:

(show top 50) (show all 155)
# Title Authors PMID Year
1
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. 56 6
18334619 2008
2
A mechanistic classification of clinical phenotypes in neuroblastoma. 56
30523111 2018
3
Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. 56
27383785 2016
4
Telomerase activation by genomic rearrangements in high-risk neuroblastoma. 56
26466568 2015
5
The genetic landscape of high-risk neuroblastoma. 56
23334666 2013
6
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. 56
23202128 2013
7
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. 56
22367537 2012
8
miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. 56
20871609 2010
9
Paraganglioma, neuroblastoma, and a SDHB mutation: Resolution of a 30-year-old mystery. 56
20503330 2010
10
ALK-Related Neuroblastic Tumor Susceptibility 6
20301782 2010
11
A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. 6
18726616 2008
12
Cancer: A ringleader identified. 56
18923503 2008
13
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. 56
18463370 2008
14
Potentiation of neuroblastoma metastasis by loss of caspase-8. 56
16397500 2006
15
A novel gene family NBPF: intricate structure generated by gene duplications during primate evolution. 56
16079250 2005
16
Chromosome 1p and 11q deletions and outcome in neuroblastoma. 56
16306521 2005
17
Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma. 56
12687660 2003
18
Screening of infants and mortality due to neuroblastoma. 56
11932470 2002
19
Neuroblastoma screening at one year of age. 56
11932471 2002
20
Analyses of apoptotic regulators CASP9 and DFFA at 1P36.2, reveal rare allele variants in human neuroblastoma tumours. 56
11870543 2002
21
Neuroblastoma within a congenital orbital teratoma. 56
11831928 2002
22
Neuroblastoma in two siblings supports the role of 1p36 deletion in tumor development. 56
10087945 1999
23
NB4S, a member of the TBC1 domain family of genes, is truncated as a result of a constitutional t(1;10)(p22;q21) chromosome translocation in a patient with stage 4S neuroblastoma. 56
9618176 1998
24
Homozygous deletion of the neurofibromatosis-1 gene in the tumor of a patient with neuroblastoma. 56
9169039 1997
25
Anticipation in pediatric malignancies. 56
9150177 1997
26
Familial predisposition to neuroblastoma does not map to chromosome band 1p36. 56
8758905 1996
27
Molecular characterization of a (1;10)(p22;q21) constitutional translocation from a patient with neuroblastoma. 56
7621412 1995
28
A region of consistent deletion in neuroblastoma maps within human chromosome 1p36.2-36.3. 56
7777541 1995
29
Evidence for two tumour suppressor loci on chromosomal bands 1p35-36 involved in neuroblastoma: one probably imprinted, another associated with N-myc amplification. 56
7633401 1995
30
Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. 56
8037211 1994
31
Nm23-H1 mutation in neuroblastoma. 56
8047138 1994
32
Allelic loss of chromosome 1p36 in neuroblastoma is of preferential maternal origin and correlates with N-myc amplification. 56
8102298 1993
33
Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. 56
8102299 1993
34
Neurofibromatosis type 1 gene mutations in neuroblastoma. 56
8490657 1993
35
Constitutional 1p36 deletion in a child with neuroblastoma. 56
8434586 1993
36
Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. 56
1594247 1992
37
Dissociation of suppression of tumorigenicity and differentiation in vitro effected by transfer of single human chromosomes into human neuroblastoma cells. 56
1679663 1991
38
Molecular evaluation of abnormalities of the short arm of chromosome 1 in neuroblastoma. 56
1980608 1990
39
Neuroblastoma consensus deletion maps to 1p36.1-2. 56
2487156 1989
40
Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region. 56
2535035 1989
41
Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. 56
2566996 1989
42
Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. 56
2563671 1989
43
Molecular analysis of chromosome 1 abnormalities in neuroblastoma. 56
2776489 1989
44
Chromosome localization in normal human cells and neuroblastomas of a gene related to c-myc. 56
6700732 1984
45
Specific DNA sequence amplification in human neuroblastoma cells. 56
6577451 1983
46
Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour. 56
6888561 1983
47
Chromosome analysis of human neuroblastoma cell line TR14 showing double minutes and an aberration involving chromosome 1. 56
6861117 1983
48
Chromosomal assignment of a family of human oncogenes. 56
6576347 1983
49
Three human transforming genes are related to the viral ras oncogenes. 56
6572964 1983
50
Isolation and preliminary characterization of the transforming gene of a human neuroblastoma cell line. 56
6300838 1983

Variations for Neuroblastoma 1

ClinVar genetic disease variations for Neuroblastoma 1:

6 (show top 50) (show all 267) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FGFR3 NM_000142.4(FGFR3):c.991T>C (p.Phe331Leu)SNV other 438762 rs1246952737 4:1805479-1805479 4:1803752-1803752
2 MAP2K4 NM_003010.4(MAP2K4):c.538C>G (p.Leu180Val)SNV other 438770 rs1555550018 17:12011131-12011131 17:12107814-12107814
3 MAP2K7 NM_145185.4(MAP2K7):c.752T>C (p.Leu251Pro)SNV other 438771 rs1555701191 19:7975941-7975941 19:7911056-7911056
4 MET NM_001127500.3(MET):c.985C>A (p.Leu329Ile)SNV other 438775 rs1554378983 7:116340123-116340123 7:116700069-116700069
5 NTRK2 NM_006180.4(NTRK2):c.970T>A (p.Leu324Met)SNV other 438780 rs201362502 9:87342685-87342685 9:84727770-84727770
6 PHF6 NM_001015877.2(PHF6):c.119C>A (p.Ala40Glu)SNV other 438782 rs1556013242 X:133511766-133511766 X:134377736-134377736
7 RBM15 NM_022768.4(RBM15):c.1912C>A (p.Gln638Lys)SNV other 438785 rs1553224979 1:110883939-110883939 1:110341317-110341317
8 TSC2 NM_000548.5(TSC2):c.3284+1G>TSNV other 438793 rs45517289 16:2129430-2129430 16:2079429-2079429
9 ALK NM_004304.5(ALK):c.3512T>C (p.Ile1171Thr)SNV Pathogenic 545115 rs1057519698 2:29445213-29445213 2:29222347-29222347
10 FANCA NM_000135.4(FANCA):c.4261-2A>CSNV Pathogenic 545114 rs915983602 16:89805118-89805118 16:89738710-89738710
11 ALK NM_004304.5(ALK):c.3512T>A (p.Ile1171Asn)SNV Pathogenic 375888 rs1057519698 2:29445213-29445213 2:29222347-29222347
12 ALK NM_004304.5(ALK):c.3735C>G (p.Phe1245Leu)SNV Pathogenic 375885 rs863225284 2:29436858-29436858 2:29213992-29213992
13 ALK NM_004304.5(ALK):c.3521T>G (p.Phe1174Cys)SNV Pathogenic 375887 rs1057519697 2:29443696-29443696 2:29220830-29220830
14 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
15 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
16 ALK NM_004304.5(ALK):c.3833A>C (p.Tyr1278Ser)SNV Pathogenic 217858 rs863225285 2:29432655-29432655 2:29209789-29209789
17 ALK NM_004304.5(ALK):c.3734T>G (p.Phe1245Cys)SNV Pathogenic 217856 rs863225283 2:29436859-29436859 2:29213993-29213993
18 ALK NM_004304.5(ALK):c.3520T>A (p.Phe1174Ile)SNV Pathogenic 217850 rs281864719 2:29443697-29443697 2:29220831-29220831
19 FGFR1 NM_023110.2(FGFR1):c.1638C>A (p.Asn546Lys)SNV Pathogenic 224896 rs779707422 8:38274849-38274849 8:38417331-38417331
20 KIF1B NM_015074.3(KIF1B):c.4442G>A (p.Ser1481Asn)SNV Pathogenic,risk factor 4662 rs121908164 1:10425534-10425534 1:10365476-10365476
21 PTPN11 NM_002834.4(PTPN11):c.226G>A (p.Glu76Lys)SNV Pathogenic 13336 rs121918464 12:112888210-112888210 12:112450406-112450406
22 PTPN11 NM_002834.4(PTPN11):c.227A>G (p.Glu76Gly)SNV Pathogenic 13338 rs121918465 12:112888211-112888211 12:112450407-112450407
23 PTPN11 NM_002834.4(PTPN11):c.227A>C (p.Glu76Ala)SNV Pathogenic 13339 rs121918465 12:112888211-112888211 12:112450407-112450407
24 ALK NM_004304.5(ALK):c.3452C>T (p.Thr1151Met)SNV Pathogenic,risk factor 18086 rs113994091 2:29445273-29445273 2:29222407-29222407
25 ALK NM_004304.5(ALK):c.3520T>G (p.Phe1174Val)SNV Pathogenic 65670 rs281864719 2:29443697-29443697 2:29220831-29220831
26 ALK NM_004304.5(ALK):c.3733T>G (p.Phe1245Val)SNV Pathogenic 65671 rs281864720 2:29436860-29436860 2:29213994-29213994
27 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
28 ALK NM_004304.5(ALK):c.3749T>C (p.Ile1250Thr)SNV Pathogenic/Likely pathogenic 21867 rs113994092 2:29432739-29432739 2:29209873-29209873
29 ALK NM_004304.5(ALK):c.3824G>A (p.Arg1275Gln)SNV Pathogenic/Likely pathogenic,risk factor 18083 rs113994087 2:29432664-29432664 2:29209798-29209798
30 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala)SNV Pathogenic/Likely pathogenic,risk factor 18084 rs113994088 2:29445450-29445450 2:29222584-29222584
31 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro)SNV Pathogenic/Likely pathogenic,risk factor 18085 rs113994089 2:29443642-29443642 2:29220776-29220776
32 ALK NM_004304.5(ALK):c.3733T>A (p.Phe1245Ile)SNV Pathogenic/Likely pathogenic 217855 rs281864720 2:29436860-29436860 2:29213994-29213994
33 ALK NM_004304.5(ALK):c.3522C>G (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217852 rs863225281 2:29443695-29443695 2:29220829-29220829
34 ALK NM_004304.5(ALK):c.3522C>A (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217851 rs863225281 2:29443695-29443695 2:29220829-29220829
35 ALK NM_004304.5(ALK):c.3520T>C (p.Phe1174Leu)SNV Pathogenic/Likely pathogenic 217849 rs281864719 2:29443697-29443697 2:29220831-29220831
36 PTPN11 NM_002834.4(PTPN11):c.214G>A (p.Ala72Thr)SNV Pathogenic/Likely pathogenic 177754 rs121918453 12:112888198-112888198 12:112450394-112450394
37 TP53 NM_000546.5(TP53):c.842A>T (p.Asp281Val)SNV Pathogenic/Likely pathogenic 182968 rs587781525 17:7577096-7577096 17:7673778-7673778
38 KIF1B NM_015074.3(KIF1B):c.1937A>T (p.Glu646Val)SNV risk factor 4659 rs121908161 1:10357264-10357264 1:10297206-10297206
39 TP53 NM_000546.5(TP53):c.841G>C (p.Asp281His)SNV Likely pathogenic 376588 rs764146326 17:7577097-7577097 17:7673779-7673779
40 TP53 NM_000546.5(TP53):c.842A>C (p.Asp281Ala)SNV Likely pathogenic 376589 rs587781525 17:7577096-7577096 17:7673778-7673778
41 ALK NM_004304.5(ALK):c.3733T>C (p.Phe1245Leu)SNV Likely pathogenic 376712 rs281864720 2:29436860-29436860 2:29213994-29213994
42 ALK NM_004304.5(ALK):c.3497T>G (p.Met1166Arg)SNV Likely pathogenic 376713 rs1057520019 2:29445228-29445228 2:29222362-29222362
43 SMARCA4 NM_001128849.2(SMARCA4):c.535C>T (p.Gln179Ter)SNV Likely pathogenic 590848 rs1469271544 19:11097044-11097044 19:10986368-10986368
44 MYC NM_002467.6(MYC):c.218C>T (p.Thr73Ile)SNV Likely pathogenic 376300 rs756091827 8:128750681-128750681 8:127738435-127738435
45 ALK NM_004304.5(ALK):c.3824G>T (p.Arg1275Leu)SNV Likely pathogenic 376365 rs113994087 2:29432664-29432664 2:29209798-29209798
46 FGFR1 NM_015850.4(FGFR1):c.1630A>G (p.Asn544Asp)SNV Likely pathogenic 376429 rs1057519898 8:38274851-38274851 8:38417333-38417333
47 FGFR1 NM_015850.4(FGFR1):c.1537A>G (p.Met513Val)SNV Likely pathogenic 376430 rs1057519899 8:38275397-38275397 8:38417879-38417879
48 MYC NM_002467.6(MYC):c.217A>C (p.Thr73Pro)SNV Likely pathogenic 376458 rs750664148 8:128750680-128750680 8:127738434-127738434
49 MYC NM_002467.6(MYC):c.173C>T (p.Pro58Leu)SNV Likely pathogenic 376459 rs1057519918 8:128750636-128750636 8:127738390-127738390
50 MYCN , MYCNOS NM_005378.6(MYCN):c.131C>T (p.Pro44Leu)SNV Likely pathogenic 376460 rs1057519919 2:16082317-16082317 2:15942195-15942195

Expression for Neuroblastoma 1

Search GEO for disease gene expression data for Neuroblastoma 1.

Pathways for Neuroblastoma 1

Pathways related to Neuroblastoma 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.63 TP53 PTPN11 FGFR1
2 11.44 TP53 PTPN11 FGFR1
3 11.03 TP53 PTPN11
4 10.93 PTPN11 FGFR1
5 10.09 TP53 FANCA

GO Terms for Neuroblastoma 1

Biological processes related to Neuroblastoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to UV GO:0009411 9.16 UBE4B TP53
2 brain development GO:0007420 9.13 PTPN11 FGFR1 ALK
3 regulation of cell proliferation GO:0042127 8.92 TP53 FGFR1 FANCA ALK

Molecular functions related to Neuroblastoma 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.1 UBE4B TP53 NAV2 KIF1B FGFR1 ALK

Sources for Neuroblastoma 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....